Background: Gastrointestinal (GI) symptoms, such as nausea and bloating, are com-
| INTRODUC TI ON
Globally, the incidence of diabetes mellitus is increasing.
1
Approximately 5% of people with diabetes suffer from type 1 diabetes mellitus (T1DM), characterized by a paucity of insulin secretion. Treatment aims to minimize hypo/hyperglycemic excursions and reduce long-term complications. Neuropathic complications are common and can manifest in the periphery, centrally or in the autonomic nervous system (ANS) and are associated with a significant socioeconomic burden. 2 Structurally, peripheral neuropathy is characterized by demyelination and axonal loss, in contrast to functional neuropathy where there is a reduction in the quality of neuronal signaling due to compromise in synaptic interconnections, which are particularly vulnerable to hyperglycemia. 3, 4 There is emerging evidence in T1DM that peripheral neuropathy and autonomic neuropathy frequently coexist possibly due to a shared pathogenesis. 5, 6 The secreto-motor function of the gastrointestinal (GI) tract is coordinated by a complex bidirectional pathway referred to as the gut-brain axis, 7 including synaptic interconnections of the enteric nervous system (ENS) and ANS. The ANS is composed of two broadly opposing branches consisting of the sympathetic and parasympathetic nervous systems. The main neural substrate of the latter is the vagus nerve, which innervates the entirety of the GI tract, except the distal third of the colon, and mediates secreto-motor effects. In particular, the vagus nerve is considered to stimulate hydrochloric acid (HCl) secretion from gastric parietal cells and historically vagotomy was a common intervention for peptic ulcer disease.
8
In diabetic autonomic neuropathy, vagal function is frequently adversely affected leading to bothersome symptoms such as early satiety, nausea and fullness which may indicate the development of GI dysmotility. 6, 9 Hitherto, the majority of research in this patient group has been directed toward investigation of transit and motility abnormalities in the stomach, though recent evidence now suggests that dysmotility in diabetes may represent a pan-enteric phenomenon. 10, 11 However, the association between symptoms and motility measures (specifically segmental and pan-enteric transit times)
remains unclear 8 and furthermore the role of concomitant factors such as glycemic control, microbiota, and genetics have only been sparsely investigated.
12,13
The wireless motility capsule (WMC) is a validated technique that concurrently measures temperature, pH, and pressure throughout the GI tract and has been applied to the evaluation of patients with diabetes. 14, 15 While stereotypical changes in pH profiles are used to identify segmental transit times, surprisingly little attention has been afforded to investigating regional pH profiles and their associations with symptoms. GI pH has been studied across a number of primary GI disorders including reflux disease, 16 idiopathic gastroparesis, 17 small intestinal bacterial overgrowth 18 , and irritable bowel syndrome. 19, 20 Furthermore, the GI pH profile have also been studied in systemic disorders, which have GI manifestations such as Parkinson's disease, 21, 22 Ehlers Danlos syndrome, 23 scleroderma
24
, and diabetes.
20
Moreover, GI pH has recently been proposed as a surrogate marker of fermentation and dysbiosis. 20, 25 We hypothesized that a cohort of people with T1DM and confirmed diabetic sensory peripheral neuropathy (DSPN) would have altered regional pH profiles in comparison to healthy subjects, and this would be associated with symptoms, clinical parameters and objective markers of autonomic neuropathy. Thus, the primary aim of this study was to investigate the difference in median gastric pH between patients with T1DM
and DSPN as compared to healthy subjects. Secondary endpoints were to compare regional GI pH profiles in T1DM patients in comparison to healthy subjects, associations between pH-profile and GI symptoms. Furthermore, we aimed to investigate whether transit times, duration of T1DM, glycaemic control and insulin usage, or other clinical parameters were associated with pH findings. Data from age-matched healthy subjects were selected from an established normative data set. 26 All healthy subjects had normal bowel
| MATERIAL S AND ME THODS

| Study population
Key Points
• Gastrointestinal symptoms, possibly caused by autonomic dysfunction, are common in people with type 1 diabetes.
• We investigated the gastrointestinal pH-profile and showed that type 1 diabetes had a more acidic environment in the stomach and colon in comparison to healthy.
• This study highlights that gastrointestinal pH is associated to clinical symptoms and may be an important factor in the development and maintenance of gastrointestinal symptoms in type 1 diabetes.
movements, no GI symptoms, and no history of cardiovascular, endocrine, renal, or chronic disease known to influence the GI tract. In addition, no healthy subjects had undergone GI surgery, other than appendectomy and/or cholecystectomy, and none were taking either laxatives or medications known to influence GI motility or pH, such as proton pump inhibitors or H2 receptors antagonists.
| Wireless motility capsule
The 
| Study protocol
After fasting overnight, the test was initiated by ingestion of a standardized meal consisting of a SmartBar (Medtronic, Minneapolis, USA, 260-kcal, composed of 3% fat, 21% protein and 75% carbohydrate, 3% of which is fiber). Subsequently, the WMC was ingested with a 50 ml glass of water. Participants were instructed to wear the portable receiver in close proximity to the abdomen until expulsion of the WMC was confirmed. Following ingestion, subjects were instructed to refrain from eating during the first 6 hours of the test, in order to assess gastric emptying under the influence of the test meal only. After 6 hours, normal individual diet and daily activities were resumed. 27 Subjects were instructed to keep a diary for the duration of the study, to record events such as bowel movement, food and liquid intake, sleep, and any GI symptoms experienced.
| Questionnaires
The Patient Assessment of Upper Gastrointestinal DisordersSymptom Severity Index (PAGI-SYM) questionnaire was filled out by people with T1DM in order to evaluate GI symptoms experienced 2 weeks prior to the study. PAGI-SYM has proven to be a reliable tool for measuring upper GI symptoms. 28 From PAGI-SYM, measurements of bloating (two items), nausea (three items), fullness (four items), and the combined score Gastroparesis Cardinal Symptom Index (GCSI) were evaluated, with measurements ranging from 0 (no symptoms) to 5 (very severe symptoms). 29 The
Gastrointestinal Symptom Rating Scale (GSRS) was also filled in by patients, in order to evaluate pan-enteric GI symptoms 2 weeks prior to the study. From the GSRS, measurements of abdominal pain (three items), reflux syndrome (two items), diarrhea syndrome (three items), indigestion syndrome (four items), and constipation syndrome (three items) were evaluated, with measurements ranging from 0 (no symptoms) to 6 (very severe symptoms). 
| Wireless motility capsule data analysis
The WMC data were analyzed using a commercially available software package (MotiliGI, version 3.0, Medtronic, Minneapolis, USA). Data were analyzed by one observer (ALW) and discrepancies were resolved through consensus with two independent observers (CB and ADF).
| Definition of anatomical landmarks
As per the method proposed by Sarosiek et al, the GI tract was divided into gastric, small bowel, and large bowel regions based on identification of stereotypical physiological pH landmarks and temperature. 15, 27 The gastric region was demarcated from the increase in temperature reflecting ingestion of the capsule to a steep rise in the pH value reflecting the capsule's expulsion from the stomach, across the pylorus, into the duodenum. The small bowel region was demarcated from entry into the duodenum to an abrupt drop in pH of more than 1 pH unit and sustained for at least 10 minutes, reflecting the capsule's passage across the ileocecal junction into the cecum. 25, 31, 32 The large bowel region was demarcated from entry into the cecum, to a rapid drop in temperature or by loss of signal reflecting expulsion of the capsule during defecation.
| Measurements
For each of the aforementioned regions, pH values of the median H + -concentration were measured. Furthermore, as per the method proposed by Zarate et al, the magnitude of the pH drop across the ileocecal junction (∆ICJ) was defined as the fall in pH from the pH peak in the ileum to its nadir value in the cecum/ascending large bowel.
26,32
Conversely, the magnitude of the pH rise across the pylorus (∆py-lorus) was measured as the difference in pH from gastric nadir pH to duodenal peak pH. 26 Additionally, transit times from each of the GI region were measured and the results has previously been published by Farmer et al. 
| Study endpoints
The primary endpoint was the difference in median gastric pH between patients with T1DM and DSPN as compared to healthy subjects.
Secondary endpoints were differences in regional pH comparison between patients with T1DM and healthy subjects, and to investigate the association between regional median pH and GI symptoms, transit times, physiological, and clinical parameters in patients and to investigate the association between glycaemic control and transit times.
| Statistical analysis
Categorical variables are expressed as percentages and Chi-squared tests/Fisher's exact tests were used to compare groups. Continuous variables are expressed as mean ± standard deviation (SD) or median and interquartile range (IQR) based upon data distribution, which was assessed using Shapiro Wilk testing and visual inspection of histograms. Bootstrapping was applied on pH data as these are log-transformed data. Bootstrapping is an approach of re-sampling data with replacements that allows test datasets to approximate the original nonparametric dataset, as parametric, without applying long-winded error-prone analytical calculations. 33 Bootstrapping has been reported to be robust with good accuracy and higher power for small to moderate sample sizes, 34 in order to quantify the variety, and thereby provide reliable confidence-intervals. In this study, the test dataset was based on 1000 bootstrap samples. 35 Differences between the two groups were assessed using a two-way factor analyses with bootstrap re-sampling. Individual region differences were identified with contrast interactions. Where results were significant between the two groups, Pearson's correlation coefficient was used to examine the association between patient's regional/∆pH and symptoms, transit times, physiological and clinical parameters.
If correlation were found between regional pH and symptoms, a sub analysis of the upper and lower pH quartiles would be performed and compared with a Students' t test. Based on previously reported 26 normative data for the primary outcome (gastric pH 2.15 ± 1.45), a sample size of 41 patients and 41 healthy subjects had in excess of 80% power, at a two-sided alpha of 0.05, to detect a difference of 1 pH unit. Statistical significance was assumed at P < 0.05 and the analysis was undertaken using Stata version 14 (StataCorp LP, Texas, USA).
| RE SULTS
All patients and healthy subjects completed the study without any complications. There were no significant demographic differences between the two groups, see Table 1 . 
Transit times-As
previously reported by Farmer et al, 11 patients had significantly longer small and large bowel transit times in com
| WMC data fidelity
Of the 89 WMC files (48 patients and 41 subjects) available for analysis, one patient's recording had major signal loss and was excluded as regional pH could not be determined. Overall WMC data quality was acceptable, with pH being identifiable in almost 90% of cases.
Data points were missing in 10 WMC traces comprising of: (i) gastric median pH in seven traces (8%); (ii) magnitude of pH change across the pylorus in two traces (2.2%) and; (iii) the magnitude of pH change across the ICJ in one trace (1.1%) (Figure 1 ).
| Regional pH profile
Gastric pH-The median gastric pH was lower in patients in comparison to healthy subjects (1.8 ± 1.6 vs 2.9 ± 1.5, P = 0.001). ∆Pyloric pH-The magnitude of pH change across the pylorus was lower in patients in comparison to healthy subjects (5.2 ± 1.5 vs 5.8 ± 0.5, P = 0.003). Small bowel pH-There was no difference in median pH between the two groups (7.1 ± 0.4 vs 7.1 ± 0.5, P = 0.520). ∆ICJ pH-As has previously been reported, 11 the magnitude of pH change across the ICJ was higher in patients compared to healthy subjects (1.8 ± 0.4 vs 1.3 ± 0.4, P < 0.0001). Large bowel pH-The median large bowel pH was lower in patients in comparison to healthy subjects (6.7 ± 0.6 vs 7.0 ± 0.5, P < 0.003), see Table 2 . The median pH across the gastric, small bowel and large bowel regions, in both patients and healthy subjects, are summarized in Figure 2 .
| Association between regional pH and symptoms
Median gastric pH did not correlate with symptoms as measured by the GSCI. Median small bowel pH positively correlated with nausea and vomiting (r = 0.42, P = 0.005). Median large bowel pH positively correlated with nausea and vomiting (r = 0.35, P = 0.018), and the total GCSI score (r = 0.34, P = 0.023). There was no correlation between symptoms, as measured by the GSRS, and any regional pH, rise across the pylorus or drop across the ICJ. GCSI and bloating scores were different in the subgroups representing high vs low large bowel pH (0.84 ± 0.86 vs 0.26 ± 0.32, P = 0.049 and 1.17 ± 1.32 vs 0.27 ± 0.52, P = 0.048, respectively), meaning that higher pH was associated with more GI symptoms.
| Association between regional pH and transit time
Median gastric pH and median small bowel pH were positively associated with small bowel time (r = 0.30, P = 0.049 and r = 0.48, P = 0.0007, respectively). Large bowel pH, the rise across the pylorus and the drop across the ICJ was not associated with transit times.
| Association between regional pH, physiological, and clinical parameters
No associations were found between median gastric pH, median small bowel pH, median large bowel pH, ∆ICJ pH and age, disease duration, HbA1c, fasting glycose levels 1 day before and on the day of the study, insulin consumption and RR-intervals. While no associations were seen between Δpylorus and age, disease duration, HbA1c, insulin consumption, and RR-intervals, there was a negative association with fasting glucose levels drawn on the morning of the study (r = −0.34, P = 0.033). Additionally, fasting glucose levels on the morning of the study were also found to negatively associate to gastric emptying time (r = −0.35, P = 0.027), but not to other transit times.
| D ISCUSS I ON
In this study, we have demonstrated that T1DM patients with confirmed DSPN have a significantly altered pH profile throughout the GI tract in comparison to healthy subjects. The objective assessment of regional pH showed that patients have a relatively more acidic environment within the stomach and large bowel as a whole, but a more alkaline environment in the small bowel. The pH profile was associated with symptoms, particularly nausea and vomiting subscales from GCSI. However, there was no association between pH profile and age, disease duration, glycaemic control, or insulin usage. In addition, pH across the pylorus was negatively associated to fasting glucose the morning of the study.
The vagus nerves exert a pivotal role in the regulation and maintenance of homeostasis, secretion of digestive hormones, and motility within the GI tract. A plausible hypothesis is that diabetic autonomic neuropathy compromises the vagus nerve resulting in alterations in GI secreto-motor function itself leading to changes in the GI microenvironment which ultimately may change intra-luminal pH, GI motility patterns or both. 8, 36 Secretion of HCl from gastric parietal cells is, in part, influenced by the vagus nerve. 8 Feldman et al showed that gastric acid secretion in the stomach of patients with diabetes and vagal neuropathy mimicked the clinical picture observed in those with delayed gastric emptying following surgical truncal vagotomy. 37 Therefore, it would be expected that compromised vagal function would result in heightened gastric pH due to a reduction in HCl secretion. 8, 37 Previously the gastric pH profile has been studied in a cohort of 20 people with either type 1-or type 2 diabetes and HbA1c < 10%, who were fed the eggbeater meal. 17 These findings show significantly increased pH in patients with diabetes, supporting compromised HCl secretion. Unexpectedly however, we demonstrated that the type 1 diabetes patients with verified DSPN, had a lower median pH in the stomach, thus challenging the classical aforementioned understanding. However, it must be noted that five patients did have elevated gastric pH, suggesting different sub-types. The present cohort was studied using the SmartBar ® , there was no upper limit of the HbA1C and neurological disorders were excluded. These differences may account for some of the differences between the studies. However, as DSPN and autonomic neuropathy often coexist, the present findings may rather be an indirect consequence of more severe vagus nerve F I G U R E 1 A characteristic WMC trace of A) a healthy subject and B) a patient with type 1 diabetes. Temperature (blue line), contractility (red lines) and pH (green line). The trace is divided into 3 regions: 1) the gastric region (G) from capsule ingestion to pylorus, 2) the small bowel region (SB) from pylorus to ileocecal junction, 3) the large bowel region (C) from the ileocecal junction to capsule expulsion dysfunction, as the vagus nerve regulates both stimulatory and inhibitory signaling of gastric acid secretion, through its mixed, afferent, and efferent function.
38
There was no association between decreased pH in the stomach and GET. Such an association could have indicated that the exposure of nutrients stimulating the gastric mucosa would lead to enhanced
HCl secretion. However, as this was not the case, the dysregulated HCl secretion may be the result of lack of inhibition rather than due to enhanced secretion. 39 Small bowel dysfunction is known to occur in patients with diabetes, and prolonged transit times have been described in up to 80% of those with coexisting gastroparesis. 11, 40 Roland et al reported that
prolongation of SBTT was associated with small intestinal bacterial overgrowth (SIBO) as measured with a lactulose hydrogen breath test. 41 In our previous study, we demonstrated that 19% of patients had delayed small bowel transit. 11 In this study we have measured small bowel pH directly, and found that it was higher in diabetes patients, potentially indicating the presence of concomitant SIBO. Furthermore, we have found a positive correlation between small bowel pH and SBTT supporting the hypothesis. Firstly, these findings suggest that the exocrine secretion of pancreatic juice is not compromised, as the acidic contents arriving from the stomach were sufficiently buffered.
Secondly, the elevated pH in the small intestine may reflect concurrent SIBO. Finally, SIBO may manifest clinically with symptoms of nausea, vomiting and bloating possibly explaining the associations between the self-assessed symptoms and small intestinal pH.
42
The pH profile within the large bowel varies along its length. In the proximal large bowel, principally anaerobic fermentation of substrate, where its delivery from the small bowel is highest, results in short-chain fatty acid (SCFA) production such as butyrate. 32, 43 Within the distal colon, SCFA production is lower due to reduced substrate availability. 44 Fermentation processes are pH dependent, as different species of bacteria have optimal conditions at different pH values.
45
Therefore, changes in the local pH profile and the transit time within the large bowel may alter the composition of the microbiota. 45, 46 Therefore, it is possible that the relatively acidified milieu of the large bowel, seen in the T1DM cohort, may have a major impact on composition of microbiota therein potentially impacting on symptomatology.
Overall, the altered pH profile in T1DM has received remarkably little attention to date and further studies are needed to ascertain whether these findings are reproducible in people with T1DM but without neuropathy and in patients with type 2 diabetes mellitus.
This is of particular salience as the pH profile in the GI tract may influence drug absorption, as the release of a number of pharmacotherapeutic agents are pH-dependent. Premature drug release, drug instability, and a diminution in the bioavailability of oral formulations are all possible consequences.
47,48
This study is not without limitation. Firstly, we used bootstrapping as a statistical tool. In bootstrapping, the sample is treated as the population and a bootstrap sample is the same size as the original sample and drawn with replacements. Multiple bootstrap samples were pooled together to construct a sample for statistical analysis. We wanted to investigate the association between objective pH measurements and clinical data. However, pH itself being a logarithmic measure could not be employed to linear regression and therefore bootstrapping provides a way to apply linear regression on these data, without violating assumption and still obtain accurate results. 49 Secondly, only a well-characterized cohort of people with T1DM and DSPN were studied, and therefore it is impossible to comment as to the generalizability of these findings with respect to TA B L E 2 Segmental pH with confidence intervals for T1DM patients with confirmed diabetic sensory-motor peripheral neuropathy and healthy subjects. pH was generally significantly lower in the stomach and large bowel of people with diabetes then in healthy subjects, whereas no differences was found in the small bowel F I G U R E 2 Box and whiskers plot of median pH in the gastric, small bowel and large bowel of healthy subjects and patients with type 1 diabetes. **P < 0.01 and ns, P > 0.05 HS: healthy subjects, T1: patients with type 1 diabetes mellitus 
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